Testimonials
Hear What Leaders in the Field are Looking Forward to at this Year’s 2nd Annual mRNA-Based Therapeutics Summit
“The 2nd Annual mRNA-Based Therapeutics Summit brings together industry leaders and academic pioneers. The summit represents a great venue for sharing scientific developments and intellectual perspectives on mRNA medicine.”
Yusuf Erkul
CEO, Kernal Biologics
“The field is moving so quickly it is only possible to keep updated on the pace and progress through participation in forums such as this where conversations take place with those making the advancements.”
Gregory Fiore
CEO, Exacis Biotherapeutics
“This event brings together thought leaders across the industry to discuss their unique perspectives in this growing field and we look forward to sharing our insights.”
Linda Marban
CEO, Capricor Therapeutics
“This event creates a forum for the mRNA community to come together to share ideas and latest technologies in the industry.”
Joe Payne
Founder, President & CEO, Arcturus Therapeutics
"This forum serves as an excellent opportunity to share unique perspectives from key thought leaders on various ongoing innovations in the field of mRNA delivery and we look forward to sharing our insights"
Akhilesh Bhambhani
Senior Director - Biologics Drug Product Development; Tech Dev/Tech Ops, Ultragenyx
"This summit will allow us to understand how the experience with vaccines, particularly COVID vaccines which have been used by millions of people around the world, can further the field of mRNA technology and it’s use as prevention and therapeutic measures"
Rituparna Das
VP – COVID Vaccines, Moderna
"The meeting provides a stimulating platform to interact with experts in this emerging field and share thoughts and ideas that may shape the future of mRNA therapeutics"
Jenny van Asbeck - van der Wijst
CEO, Mercurna
“At this summit, I see value in learning about current non-viral vector preclinical bottlenecks such as toxicity and manufacturing. I am also interested in hearing how current nucleic acid therapeutics companies plan on tackling non-liver delivery.”
Kalina Paunovska
Postdoctoral Scholar, Georgia Institute of Technology, Dahlman Lab
“This summit is an excellent opportunity to join in the discussion with key thought leaders and innovators of one of the most impactful technologies of this generation.”
Russell Johnson
VP – Formulation Research, RVAC Medicines
“mRNA as a platform therapeutic has held promise for many years, but it is only recently that it has reached the people who can benefit from it. This meeting can help inform and differentiate from other genetic therapies and identify opportunities for synergy.”
John Marshall
Senior Director – Rare Disease, Moderna
